Predictors of prognosis in Alzheimer’s disease: The role of cognitive dysfunction, immune abnormalities, and advanced neuroimaging

doi:10.12998/wjcc.v12.i27.6004

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1147)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

677

Sum=700

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

160

Download

158

Sum=318

Publishing Process of This Article

Item

Count

Browse

Download

Sum=95

Sep 26, 2024 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Cases. Sep 26, 2024; 12(27): 6004-6006
Published online Sep 26, 2024. doi: 10.12998/wjcc.v12.i27.6004

Predictors of prognosis in Alzheimer’s disease: The role of cognitive dysfunction, immune abnormalities, and advanced neuroimaging

Hafsa Arshad Raja, Abdulqadir J Nashwan

Hafsa Arshad Raja, Rawalpindi Medical University, Rawalpindi 46000, Pakistan

Abdulqadir J Nashwan, Department of Nursing, Hamad Medical Corporation, Doha 3050, Qatar

Author contributions: Raja HA contributed to the manuscript's writing, editing, and literature review; Nashwan AJ contributed to the manuscript's writing, editing, and literature review.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Abdulqadir J Nashwan, MSc, Research Scientist, Department of Nursing, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa

Received: February 5, 2024
Revised: May 18, 2024
Accepted: June 14, 2024
Published online: September 26, 2024
Processing time: 176 Days and 8.3 Hours

Core Tip

Core Tip: Alzheimer’s disease (AD) is a serious condition leading to cognitive and social challenges. A recent study found that poor prognosis in AD patients is linked to abnormal cellular immune function, extrapyramidal symptoms, altered consciousness, abnormal electroencephalogram, increased neutrophil-lymphocyte ratio, and severe pneumonia. Impaired cellular immune function, particularly reduced T lymphocytes in the blood, is an independent predictor of poor prognosis. Early and continuous use of AD medications is associated with better outcomes.